173 related articles for article (PubMed ID: 23217168)
21. Chemoprevention of colorectal cancer: ready for routine use?
Arber N; Levin B
Recent Results Cancer Res; 2005; 166():213-30. PubMed ID: 15648192
[TBL] [Abstract][Full Text] [Related]
22. Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors.
Harris RE; Beebe-Donk J; Alshafie GA
BMC Cancer; 2008 Aug; 8():237. PubMed ID: 18702823
[TBL] [Abstract][Full Text] [Related]
23. Chemoprevention of colorectal cancer with cyclooxygenase-2 inhibitors: two steps forward, one step back.
Bertagnolli MM
Lancet Oncol; 2007 May; 8(5):439-43. PubMed ID: 17466901
[TBL] [Abstract][Full Text] [Related]
24. Chemoprevention of colorectal neoplasia: advances and controversies (the COX-2 story).
Bresalier RS
Curr Opin Gastroenterol; 2007 Jan; 23(1):44-7. PubMed ID: 17133084
[TBL] [Abstract][Full Text] [Related]
25. COX-2 active agents in the chemoprevention of colorectal cancer.
Kraus S; Naumov I; Arber N
Recent Results Cancer Res; 2013; 191():95-103. PubMed ID: 22893201
[TBL] [Abstract][Full Text] [Related]
26. Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer.
Chell S; Kaidi A; Williams AC; Paraskeva C
Biochim Biophys Acta; 2006 Aug; 1766(1):104-19. PubMed ID: 16859832
[TBL] [Abstract][Full Text] [Related]
27. Use of Selective Cyclooxygenase-2 Inhibitors, Other Analgesics, and Risk of Glioma.
Seliger C; Meier CR; Becker C; Jick SS; Bogdahn U; Hau P; Leitzmann MF
PLoS One; 2016; 11(2):e0149293. PubMed ID: 26871579
[TBL] [Abstract][Full Text] [Related]
28. COX-2 polymorphisms and colorectal cancer risk: a strategy for chemoprevention.
Pereira C; Pimentel-Nunes P; Brandão C; Moreira-Dias L; Medeiros R; Dinis-Ribeiro M
Eur J Gastroenterol Hepatol; 2010 May; 22(5):607-13. PubMed ID: 20075740
[TBL] [Abstract][Full Text] [Related]
29. The role of statins for primary prevention in non-elderly colorectal cancer patients.
Sehdev A; Shih YC; Huo D; Vekhter B; Lyttle C; Polite B
Anticancer Res; 2014 Sep; 34(9):5043-50. PubMed ID: 25202089
[TBL] [Abstract][Full Text] [Related]
30. Clopidogrel and Low-Dose Aspirin, Alone or Together, Reduce Risk of Colorectal Cancer.
Rodríguez-Miguel A; García-Rodríguez LA; Gil M; Montoya H; Rodríguez-Martín S; de Abajo FJ
Clin Gastroenterol Hepatol; 2019 Sep; 17(10):2024-2033.e2. PubMed ID: 30580092
[TBL] [Abstract][Full Text] [Related]
31. Cancer chemoprevention by cyclooxygenase 2 (COX-2) blockade: results of case control studies.
Harris RE; Beebe-Donk J; Alshafie GA
Subcell Biochem; 2007; 42():193-212. PubMed ID: 17612052
[TBL] [Abstract][Full Text] [Related]
32. Role of cyclooxygenase-2 in pathogenesis and prevention of colorectal cancer.
Hahn E; Kraus S; Arber N
Dig Dis; 2010; 28(4-5):585-9. PubMed ID: 21088406
[TBL] [Abstract][Full Text] [Related]
33. Use of an α-Glucosidase Inhibitor and the Risk of Colorectal Cancer in Patients With Diabetes: A Nationwide, Population-Based Cohort Study.
Tseng YH; Tsan YT; Chan WC; Sheu WH; Chen PC
Diabetes Care; 2015 Nov; 38(11):2068-74. PubMed ID: 26307605
[TBL] [Abstract][Full Text] [Related]
34. [Selective cyclooxygenase-2 inhibitors for the prevention of colorectal adenomas: a meta-analysis].
Jin XF; Tong JL; Ran ZH
Zhonghua Yi Xue Za Zhi; 2007 Jul; 87(28):1958-61. PubMed ID: 17923032
[TBL] [Abstract][Full Text] [Related]
35. COX-2: a molecular target for colorectal cancer prevention.
Brown JR; DuBois RN
J Clin Oncol; 2005 Apr; 23(12):2840-55. PubMed ID: 15837998
[TBL] [Abstract][Full Text] [Related]
36. The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence.
Rahme E; Barkun AN; Toubouti Y; Bardou M
Gastroenterology; 2003 Aug; 125(2):404-12. PubMed ID: 12891542
[TBL] [Abstract][Full Text] [Related]
37. Exploring the Relationship Between Colorectal Cancer and Allopurinol: A Taiwanese Population-Based Propensity-Matched Case-Control Study.
Hsu FG; Lai JN; Huang CY; Lin MC; Hsieh YW
J Clin Pharmacol; 2021 Aug; 61(8):1131-1137. PubMed ID: 33580545
[TBL] [Abstract][Full Text] [Related]
38. Celecoxib for the prevention of sporadic colorectal adenomas.
Bertagnolli MM; Eagle CJ; Zauber AG; Redston M; Solomon SD; Kim K; Tang J; Rosenstein RB; Wittes J; Corle D; Hess TM; Woloj GM; Boisserie F; Anderson WF; Viner JL; Bagheri D; Burn J; Chung DC; Dewar T; Foley TR; Hoffman N; Macrae F; Pruitt RE; Saltzman JR; Salzberg B; Sylwestrowicz T; Gordon GB; Hawk ET;
N Engl J Med; 2006 Aug; 355(9):873-84. PubMed ID: 16943400
[TBL] [Abstract][Full Text] [Related]
39. Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid.
Brown PH; Subbaramaiah K; Salmon AP; Baker R; Newman RA; Yang P; Zhou XK; Bissonnette RP; Dannenberg AJ; Howe LR
Cancer Prev Res (Phila); 2008 Aug; 1(3):208-14. PubMed ID: 19138958
[TBL] [Abstract][Full Text] [Related]
40. Chemoprevention of cancers in gastrointestinal tract with cyclooxygenase 2 inhibitors.
Wang R; Guo L; Wang P; Yang W; Lu Y; Huang Z; Tang C
Curr Pharm Des; 2013; 19(1):115-25. PubMed ID: 22950494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
